A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia

Clinical Cancer Research

Volumn 23, Issue 3, 2017, Pages 697-706

  Gojo, Ivana ^a   Beumer, Jan H ^b,c   Pratz, Keith W ^a   McDevitt, Michael A ^a,h   Baer, Maria R ^d   Blackford, Amanda L ^a   Smith, B Douglas ^a   Gore, Steven D ^a,i   Carraway, Hetty E ^a,j   Showel, Margaret M ^a   Levis, Mark J ^a   Dezern, Amy E ^a   Gladstone, Douglas E ^a   Ji, Jiuping Jay ^e   Wang, Lihua ^e   Kinders, Robert J ^e   Pouquet, Marie ^c   Ali Walbi, Ismail ^c   Rudek, Michelle A ^a   Poh, Weijie ^a   Herman, James G ^a,b   Karnitz, Larry M ^f   Kaufmann, Scott H ^f   Chen, Alice ^g   Karp, Judith E ^a   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e SAIC FREDERICK INC   (United States)

^f MAYO CLINIC   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h ASTRAZENECA   (United Kingdom)

ⁱ YALE CANCER CENTER   (United States)

^j TAUSSIG CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; BRCA1 PROTEIN; CD34 ANTIGEN; GLUCOSE; HISTONE H2AX; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MUTL PROTEIN HOMOLOG 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHORUS; POLY(ADENOSINE DIPHOSPHATE RIBOSE); SODIUM; TEMOZOLOMIDE; VELIPARIB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; H2AFX PROTEIN, HUMAN; HISTONE; MGMT PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PARP1 PROTEIN, HUMAN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ABDOMINAL PAIN; ACUTE MYELOID LEUKEMIA; ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPERGILLOSIS; ASPIRATION PNEUMONIA; BACKACHE; BACTEREMIA; BLAST CELL; CELLULITIS; CHILL; CHOLECYSTITIS; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DNA DAMAGE; DNA METHYLATION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPNEA; ELIMINATION HALF-LIFE; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUSHING; HEART EDEMA; HISTONE PHOSPHORYLATION; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; ILEUS; INGUINAL HERNIA; INSOMNIA; LEUKEMIA CELL; LUNG MYCOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPHIL COUNT; ORAL MUCOSITIS; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RASH; RESPIRATORY FAILURE; SEPSIS; SIDE EFFECT; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH INFECTION; VOLUME OF DISTRIBUTION; WEAKNESS; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MUCOSA INFLAMMATION; PHOSPHORYLATION; PROTEIN PROCESSING; REMISSION; SALVAGE THERAPY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG SYNERGISM; ESOPHAGITIS; FEMALE; HISTONES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MUCOSITIS; NEOPLASM PROTEINS; PHOSPHORYLATION; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; REMISSION INDUCTION; SALVAGE THERAPY; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 85012295487     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0984     Document Type: Article

References (41)

1. Kadia TM, Ravandi F, Cortes J, Kantarjian H. Toward individualized therapy in acute myeloid leukemia: a contemporary review. JAMA Oncol 2015;1:820-8.
2. Gojo I, Karp JE. New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. Clin Cancer Res 2014;20:6233-41.
3. Esposito MT, So CW. DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance. Chromosoma 2014;123:545-61.
4. Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 2015;33:1397-406.
5. Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGiammarino EL, et al. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res 2015;13:1465-77.
6. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72:5588-99.
7. Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, et al. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 2014;349:408-16.
8. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
9. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
10. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
11. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New Engl J Med 2009;361:123-34.
12. De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol 2013;3:228.
13. Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, et al. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol Cancer Res 2008;6:1621-9.
14. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998;54:334-41.
15. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99.
16. Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009;8:2232-42.
17. Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T. Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol 2002;20:3249-53.
18. Brandwein JM, Kassis J, Leber B, Hogge D, Howson-Jan K, Minden MD, et al. Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression. Br J Haematol 2014;167:664-70.
19. Brandwein JM, Yang L, Schimmer AD, Schuh AC, Gupta V, Wells RA, et al. A phase II study of temozolomide therapy for poor-risk patients aged>or=60 years with acute myeloid leukemia: low levels of MGMT predict for response. Leukemia 2007;21:821-4.
20. Bolanos-Meade J, Guo C, Gojo I, Karp JE. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML. Leuk Res 2004;28:571-7.
21. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-9.
22. Parise RA, Shawaqfeh M, Egorin MJ, Beumer JH. Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase. J Chromatogr B Analyt Technol Biomed Life Sci 2008;872:141-7.
23. Kim H, Likhari P, Parker D, Statkevich P, Marco A, Lin CC, et al. High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. J Pharm Biomed Anal 2001;24:461-8.
24. Tawbi HA, Beumer JH, Tarhini AA, Moschos S, Buch SC, Egorin MJ, et al. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol 2013;24:1112-9.
25. Geng L, Huntoon CJ, Karnitz LM. RAD18-mediated ubiquitination of PCNA activates the Fanconi anemia DNA repair network. J Cell Biol 2010;191:249-57.
26. Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng YC, Rowinsky EK. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood 1997;89:2098-104.
27. Kaufmann SH. Reutilization of immunoblots after chemiluminescent detection. Anal Biochem 2001;296:283-6.
28. Lamarre D, Talbot B, de Murcia G, Laplante C, Leduc Y, Mazen A, et al. Structural and functional analysis of poly(ADP ribose) polymerase: an immunological study. Biochim Biophys Acta 1988;950:147-60.
29. Griffiths EA, Gore SD, Hooker CM, Mohammad HP, McDevitt MA, Smith BD, et al. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics 2010;5:590-600.
30. Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 2010;28:e563-4.
31. Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, et al. Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. PLoS One 2011;6:e26152.
32. Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007;110:1762-9.
33. Xie Y, de Winter JP, Waisfisz Q, Nieuwint AW, Scheper RJ, Arwert F, et al. Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells. Br J Haematol 2000;111:1057-64.
34. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15.
35. Liu X, Han EK, Anderson M, Shi Y, Semizarov D, Wang G, et al. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol Cancer Res 2009;7:1686-92.
36. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015;137:386-91.
37. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012;18:1726-34.
38. Salem AH, Giranda VL, Mostafa NM. Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies. Clin Pharmacokinet 2014;53:479-88.
39. Pratz KW, Kaufmann SH, Litzow MR, Ji J, Chen A, Rudek MA, et al. Phase I trial of the oral poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888, V) combined wtih topoecan (T) and carboplatin (C) for adults with relapsed and refractory acute leukemias. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, CA. Abstract nr 3634.
40. Li J, Kim S, Sha X, Wiegand R, Wu J, LoRusso P. Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics. Clin Cancer Res 2014;20:3931-44.
41. Esposito MT, Zhao L, Fung TK, Rane JK, Wilson A, Martin N, et al. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors. Nat Med 2015;21:1481-90.